MX2016007717A - Formas solidas de un compuesto de dihidroxi ciclopentilo disustituido con alfa, omega y metodos para su preparacion y uso. - Google Patents
Formas solidas de un compuesto de dihidroxi ciclopentilo disustituido con alfa, omega y metodos para su preparacion y uso.Info
- Publication number
- MX2016007717A MX2016007717A MX2016007717A MX2016007717A MX2016007717A MX 2016007717 A MX2016007717 A MX 2016007717A MX 2016007717 A MX2016007717 A MX 2016007717A MX 2016007717 A MX2016007717 A MX 2016007717A MX 2016007717 A MX2016007717 A MX 2016007717A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- preparation
- another aspect
- present
- cyclopentyl compound
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/559—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing hetero atoms other than oxygen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/28—Halogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
En la presente se proporcionan múltiples formas sólidas de un compuesto de dihidroxi ciclopentilo disustituido con a,d definido y métodos para su preparación y uso. En un aspecto, se proporcionan formas cristalinas de dicho compuesto de ciclopentilo y métodos para su preparación y uso. En otro aspecto, se proporcionan formas sustancialmente amorfas de dicho compuesto de dihidroxi ciclopentilo y métodos para su preparación y uso. En aun otro aspecto, se proporcionan composiciones que contienen compuestos de acuerdo con la presente invención. En determinados aspectos, tales composiciones son adecuadas para la administración de agentes activos de acuerdo con la presente invención a un sujeto que lo necesita. En otro aspecto de la invención, se proporcionan métodos para el tratamiento de una variedad de indicaciones, que incluyen glaucoma, hipertensión ocular y similares. En aun otro aspecto de la presente invención, se proporcionan kits que contienen compuestos de acuerdo con la presente invención y/o composiciones que los contienen.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361915575P | 2013-12-13 | 2013-12-13 | |
| PCT/US2014/070156 WO2015089475A1 (en) | 2013-12-13 | 2014-12-12 | Solid forms of an alpha, omega di-substituted dihydroxy cyclopentyl compound and methods for the preparation and use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2016007717A true MX2016007717A (es) | 2016-09-09 |
Family
ID=52282957
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016007717A MX2016007717A (es) | 2013-12-13 | 2014-12-12 | Formas solidas de un compuesto de dihidroxi ciclopentilo disustituido con alfa, omega y metodos para su preparacion y uso. |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US9353079B2 (es) |
| EP (1) | EP3080096A1 (es) |
| JP (2) | JP2016539994A (es) |
| KR (1) | KR20160097310A (es) |
| CN (1) | CN105814033B (es) |
| AU (1) | AU2014361794B2 (es) |
| BR (1) | BR112016013594A8 (es) |
| CA (1) | CA2933556A1 (es) |
| CL (2) | CL2016001448A1 (es) |
| IL (2) | IL245917B (es) |
| MX (1) | MX2016007717A (es) |
| RU (1) | RU2730520C2 (es) |
| SA (1) | SA516371307B1 (es) |
| SG (2) | SG10201709702UA (es) |
| UA (1) | UA121108C2 (es) |
| WO (1) | WO2015089475A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10206813B2 (en) | 2009-05-18 | 2019-02-19 | Dose Medical Corporation | Implants with controlled drug delivery features and methods of using same |
| EP3658149B1 (en) * | 2017-07-25 | 2021-11-10 | Allergan, Inc. | Solid complex comprising (z)-7-((1r,2r,3r,5s)-2-((s,e)-5-(2,5-dichlorothiophen-3-yl)-3-hydroxypent-1-en-1-yl)-3,5-dihydroxycyclopentyl)hept-5-enamide, preparation and uses thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES416865A1 (es) * | 1972-07-13 | 1976-03-01 | Pfizer | Procedimiento para preparar w-pentanorprostaglandinas sus- tituidas en la posicion 15. |
| US5296504A (en) * | 1988-09-06 | 1994-03-22 | Kabi Pharmacia | Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension |
| US5834498A (en) * | 1992-09-21 | 1998-11-10 | Allergan | Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents |
| US6602900B2 (en) | 1992-09-21 | 2003-08-05 | Allergan, Inc. | Cyclopentane heptan(ENE)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents |
| US6124344A (en) * | 1993-12-28 | 2000-09-26 | Allergan Sales, Inc. | Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents |
| EP0825980B1 (en) * | 1995-05-18 | 2001-07-04 | Allergan Sales, Inc. | Cyclopentane heptan(ene)oic acid, 2-heteroarylakenyl derivatives as therapeutic agents for the treatment of ocular hypertension |
-
2014
- 2014-12-12 BR BR112016013594A patent/BR112016013594A8/pt not_active IP Right Cessation
- 2014-12-12 JP JP2016538513A patent/JP2016539994A/ja active Pending
- 2014-12-12 WO PCT/US2014/070156 patent/WO2015089475A1/en active Application Filing
- 2014-12-12 RU RU2016123446A patent/RU2730520C2/ru active
- 2014-12-12 CN CN201480067663.3A patent/CN105814033B/zh not_active Expired - Fee Related
- 2014-12-12 CA CA2933556A patent/CA2933556A1/en not_active Abandoned
- 2014-12-12 SG SG10201709702UA patent/SG10201709702UA/en unknown
- 2014-12-12 KR KR1020167018489A patent/KR20160097310A/ko not_active Application Discontinuation
- 2014-12-12 UA UAA201606260A patent/UA121108C2/uk unknown
- 2014-12-12 US US14/569,210 patent/US9353079B2/en active Active
- 2014-12-12 EP EP14824284.5A patent/EP3080096A1/en not_active Withdrawn
- 2014-12-12 MX MX2016007717A patent/MX2016007717A/es unknown
- 2014-12-12 SG SG11201604787SA patent/SG11201604787SA/en unknown
- 2014-12-12 AU AU2014361794A patent/AU2014361794B2/en not_active Ceased
-
2016
- 2016-05-05 US US15/147,700 patent/US20170087163A1/en not_active Abandoned
- 2016-05-30 IL IL245917A patent/IL245917B/en active IP Right Grant
- 2016-06-10 CL CL2016001448A patent/CL2016001448A1/es unknown
- 2016-06-13 SA SA516371307A patent/SA516371307B1/ar unknown
-
2019
- 2019-02-22 CL CL2019000471A patent/CL2019000471A1/es unknown
- 2019-12-23 JP JP2019231685A patent/JP2020073513A/ja active Pending
-
2021
- 2021-06-08 IL IL283810A patent/IL283810A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112016013594A8 (pt) | 2020-05-19 |
| US20170087163A1 (en) | 2017-03-30 |
| JP2016539994A (ja) | 2016-12-22 |
| CL2019000471A1 (es) | 2019-07-12 |
| EP3080096A1 (en) | 2016-10-19 |
| IL245917A0 (en) | 2016-08-02 |
| CA2933556A1 (en) | 2015-06-18 |
| JP2020073513A (ja) | 2020-05-14 |
| SA516371307B1 (ar) | 2018-10-04 |
| SG11201604787SA (en) | 2016-07-28 |
| SG10201709702UA (en) | 2018-01-30 |
| WO2015089475A1 (en) | 2015-06-18 |
| KR20160097310A (ko) | 2016-08-17 |
| US9353079B2 (en) | 2016-05-31 |
| CL2016001448A1 (es) | 2017-03-03 |
| AU2014361794A1 (en) | 2016-06-16 |
| US20150166504A1 (en) | 2015-06-18 |
| AU2014361794B2 (en) | 2019-04-04 |
| CN105814033B (zh) | 2019-10-25 |
| UA121108C2 (uk) | 2020-04-10 |
| IL245917B (en) | 2021-06-30 |
| RU2730520C2 (ru) | 2020-08-24 |
| IL283810A (en) | 2021-07-29 |
| CN105814033A (zh) | 2016-07-27 |
| BR112016013594A2 (es) | 2017-08-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2018236800B2 (en) | DNA-PK inhibitors | |
| EA201590748A1 (ru) | Противовирусные соединения против rsv | |
| CL2016001895A1 (es) | Compuestos | |
| CU20170077A7 (es) | Compuesto derivado de benzamida sustituida con 1,3-tiazol-2-ilo útil para el tratamiento de trastornos neurogénicos, composiciones y combinaciones que lo comprende | |
| PE20180024A1 (es) | Triazolopirazinonas como inhibidores de pde1 | |
| CL2012003427A1 (es) | Compuestos derivados de 5-amino-3,6-dihidro-1h-pirazina-2-ona; y uso en el tratamiento de enfermedades tales como alzheimer, senilidad, demencia, entre otras. | |
| UY34750A (es) | ?compuestos para el tratamiento del hiv, composiciones,métodos de preparación, intermediarios y métodos terapéuticos?. | |
| UY34201A (es) | Compuestos de azaindol y métodos para el tratamiento de vih. | |
| EA201691590A1 (ru) | Бензимидазол-2-амины в качестве ингибиторов midhi | |
| UY34395A (es) | ?Tratamiento de Esclerosis Múltiple con la Combinación de Laquinimod y Fingolimod?. | |
| DOP2016000253A (es) | Nuevos compuestos | |
| EA201691216A1 (ru) | Композиции линаклотида с замедленным высвобождением | |
| UY35276A (es) | Nuevos compuestos que inhiben la actividad de Lp-PLA2 | |
| UA113962C2 (xx) | Фармацевтична композиція, яка містить апоморфін як активний інгредієнт | |
| MX2016003823A (es) | Inhibidor selectivo de fosfatidil-inositol 3-cinasa-gamma. | |
| EA201791363A1 (ru) | Пиразолопиридинамины в качестве ингибиторов mknk1 и mknk2 | |
| EA201790687A1 (ru) | Хинолинкарбоксамиды для применения в лечении множественной миеломы | |
| AU2013408771A8 (en) | Prebiotic oral care compositions containing an alkyl glycoside | |
| DOP2016000251A (es) | Inhibidores de las vías de señalización de wnt | |
| EA201591717A1 (ru) | Твердые формы гидрохлорида вемурафениба | |
| MX366829B (es) | Composiciones y formas de dosificacion de itraconazol y metodos de uso de las mismas. | |
| MX2016007717A (es) | Formas solidas de un compuesto de dihidroxi ciclopentilo disustituido con alfa, omega y metodos para su preparacion y uso. | |
| MX2015013151A (es) | Métodos de tratamiento de disquinesia y trastornos relacionados. | |
| GT201300225A (es) | Tieno (2,3-d) derivados de pirimidina y su uso para el tratamiento de la arritmia | |
| CL2015002188A1 (es) | Agentes analgésicos oculares tópicos |